Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Post-Mkt 08-26 17:23:30 EDT

40.57

-0.65

-1.58%

盘后40.57

+0.000.00%

17:19 EDT

High42.12	Low40.06	Vol540.66K
Open41.18	D1 Closing41.22	Amplitude5.00%
Mkt Cap3.18B	Tradable Cap2.96B	Total Shares78.49M
T/O21.88M	T/O Rate0.74%	Tradable Shares73.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":40.57,"timestamp":1787774400000,"preClose":41.22,"halted":0,"volume":540663,"hourTrading":{"tag":"盘后","latestPrice":40.57,"preClose":40.57,"latestTime":"17:19 EDT","volume":18788,"amount":762225.6466440001,"timestamp":1787779184312,"change":0,"changeRate":0,"amplitude":0.015775},"delay":0,"changeRate":-0.015769044153323596,"floatShares":73018600,"shares":78492100,"eps":-4.340134,"marketStatus":"Post-Mkt","change":-0.65,"latestTime":"08-26 17:23:30 EDT","open":41.18,"high":42.12,"low":40.06,"amount":21876239.263788,"amplitude":0.049976,"askPrice":41.36,"askSize":48,"bidPrice":39.5,"bidSize":8,"shortable":3,"etf":0,"ttmEps":-4.340134,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":41.22,"preHourTrading":{"tag":"盘前","latestPrice":41,"preClose":41.22,"latestTime":"09:27 EDT","volume":1638,"amount":67829.504652,"timestamp":1787750879307,"change":-0.22,"changeRate":-0.005337,"amplitude":0.023197},"postHourTrading":{"tag":"盘后","latestPrice":40.57,"preClose":40.57,"latestTime":"17:19 EDT","volume":18788,"amount":762225.6466440001,"timestamp":1787779184312,"change":0,"changeRate":0,"amplitude":0.015775},"volumeRatio":0.643584,"impliedVol":1.0524,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/CLDX","defaultTab":"news","newsList":[{"id":"2659234121","title":"Celldex Posts Investor Presentation Highlighting Barzolvolimab Late-Stage Chronic Urticaria Program Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2659234121","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659234121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:04","pubTimestamp":1786741482,"startTime":"0","endTime":"0","summary":"Celldex posts investor presentation highlighting barzolvolimab late-stage chronic urticaria program milestonesCelldex outlined a late-stage immunology pipeline centered on barzolvolimab, a KIT antagon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL2zRfLz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658908310","title":"Celldex Therapeutics (CLDX) Reported Wider Losses, Is It Still Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658908310","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658908310?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:35","pubTimestamp":1786538126,"startTime":"0","endTime":"0","summary":"Why Celldex Therapeutics Stock Is Moving After Its Latest Earnings Report\nCelldex Therapeutics (CLDX) released second quarter and first half 2026 results, showing sharply lower revenue and a wider net loss. This earnings update is now central to how investors view the stock.\nSee our latest analysis for Celldex Therapeutics.\nThe earnings release comes after a strong run in Celldex Therapeutics' share price, with a 7 day share price return of 13.52% and a year to date share price return of...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-reported-wider-losses-is-it-still","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-reported-wider-losses-is-it-still","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","DCF","CLDX","SPHQ","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623038","title":"Celldex (CLDX) Gets a Buy from Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623038","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623038?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:15","pubTimestamp":1786130153,"startTime":"0","endTime":"0","summary":"Jefferies analyst maintained a Buy rating on Celldex today and set a price target of $68.00. In addition to Jefferies, Celldex also received a Buy ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/celldex-cldx-gets-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/celldex-cldx-gets-a-buy-from-jefferies-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657623428","title":"Celldex Therapeutics is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657623428","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657623428?lang=en_us&edition=fundamental","pubTime":"2026-08-08 03:02","pubTimestamp":1786129320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657236256","title":"Analysts Offer Insights on Healthcare Companies: Zoetis (ZTS) and Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657236256","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657236256?lang=en_us&edition=fundamental","pubTime":"2026-08-08 02:30","pubTimestamp":1786127408,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Zoetis (ZTS) and Celldex (CLDX). Zoetis (ZTS) In a report release...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zoetis-zts-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zoetis-zts-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LU0385154629.USD","LABU","LU0158827948.USD","LU2308191902.HKD","GB00BDT5M118.USD","XBI","LU1236620834.HKD","BK4007","LU1059921491.USD","BK4534","LU0471298694.HKD","BK4581","BK4588","LU1721429741.USD","LU0289739699.SGD","LU0029874061.USD","LU0345774631.USD","LU0128526141.USD","LU2271345857.HKD","LU2089283258.USD","BK4139","BK4585","LU0158827781.USD","LU1941712348.USD","LU0058720904.USD","LU2023251221.USD","LU0345774391.USD","PAWZ","LU0471298777.SGD","LU0079474960.USD","XLV","LU1721429402.USD","ZTS","LU1236620750.USD","LU2360106947.USD","LU1941712264.USD","CLDX","BK4137","LU2111349929.HKD","LU2089284900.SGD","LU2028103732.USD","LU0107464264.USD","IE00B19Z9505.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641843","title":"Celldex price target raised to $46 from $40 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657641843?lang=en_us&edition=fundamental","pubTime":"2026-08-07 21:38","pubTimestamp":1786109917,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Celldex (CLDX) to $46 from $40 and keeps an Overweight rating on the shares. Published first on Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-price-target-raised-to-46-from-40-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-price-target-raised-to-46-from-40-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666703","title":"Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666703","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666703?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:57","pubTimestamp":1786053429,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61026418/celldex-therapeutics-q2-eps-0-94-beats-1-07-estimate-sales-22-000k-miss-954-444k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668128","title":"Celldex Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668128","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668128?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:34","pubTimestamp":1786048471,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings SummaryCelldex Therapeutics, Inc.CLDX.OQreported a quarterly adjusted loss of 94 cents per share for the quarter end","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4433BW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657465743","title":"Celldex Q2 FY26 Net Loss Widens to $73.5 Million; R&D Expenses Climb to $67.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657465743","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657465743?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:08","pubTimestamp":1786046924,"startTime":"0","endTime":"0","summary":"Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 millionCelldex posted a Q2 net loss of $73.5 million, or ($0.94) per share, widening from a $56.6 million loss a year earl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL5rf7V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652436","title":"Celldex Therapeutics Q2 Revenue USD 22 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652436","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652436?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046462,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXM0KPTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656939645","title":"Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2656939645","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656939645?lang=en_us&edition=fundamental","pubTime":"2026-08-01 03:14","pubTimestamp":1785525255,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) is in focus after releasing topline results from its Phase 2 clinical trial in prurigo nodularis, a development that gives investors new information on a key pipeline program.\nSee our latest analysis for Celldex Therapeutics.\nThe Phase 2 readout arrives after a period of strong momentum in Celldex Therapeutics' stock, with a 90 day share price return of 19.11% and a year to date share price return of 42.48%. The 1 year total shareholder return of 75.09% contrasts...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-after-phase-2-trial-results-as-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cldx/celldex-therapeutics/news/celldex-therapeutics-cldx-after-phase-2-trial-results-as-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CLDX","DCF","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655981255","title":"PharmaCyte Net Loss Widens to $19.42 Million in FY26; Revenue Remains no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2655981255","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655981255?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:20","pubTimestamp":1785360011,"startTime":"0","endTime":"0","summary":"PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenuePharmaCyte Biotech posted a net loss of USD 19.42 million for fiscal 2026, swinging from net income of USD 30.66 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL4JYXWS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMCB","BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655785475","title":"U.S. Research ROUNDUP-Boeing, Coca-Cola, PayPal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655785475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655785475?lang=en_us&edition=fundamental","pubTime":"2026-07-29 15:06","pubTimestamp":1785308807,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Boeing, Coca-Cola, PayPalJuly 29 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Boeing, Coca-Cola a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL4N43V0KM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASTS","BMRC","ASH","BAC","ABBV","CAKE","BCAL","AXTA","EBC","ABG","BRO","CORT","DTE","BA","CNC","DIS","ITA","JDOC","NATO","PPA","ARWR","CNCG","LEU","BMED","CPNG","AMT","CZR","ACHC","UYG","KMX","AMGN","CFG","CSGP","CASY","CLDX","DAR","KO","CORZ","BYRE","BIIB","UTES","ALT","CNP","ECL","ENPH","GLW","CHTR","CLW","LEUX","BE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654054554","title":"Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654054554","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654054554?lang=en_us&edition=fundamental","pubTime":"2026-07-25 22:50","pubTimestamp":1784991019,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alkermes (ALKS) and Celldex (CLDX) with bullish sent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alkermes-alks-and-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","PSIL","XLV","PSCH","BK4139","IBRN","ALKS","BK4581","CLDX","HCSG","XBI","BK4585","LU0128526141.USD","MEDX","LU0029874061.USD","BK4137","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653765374","title":"U.S. Stocks on the Move-ge Vernova, Arrowhead Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2653765374","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653765374?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:55","pubTimestamp":1784728515,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-GE Vernova, Arrowhead PharmaWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nL6N43O0LY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU2505996509.AUD","GASZ","LU1280957306.USD","VDE","LU2168564149.EUR","LU2404859667.USD","LU0345781412.USD","LU2237957902.USD","LU0861579265.USD","LU0976567544.SGD","LU0792757196.USD","LU2065169927.USD","LU0690374615.EUR","LU1093756325.SGD","LU0795875169.SGD","LU0211328371.USD","SG9999002224.SGD","LU0006061336.USD","LU1571399168.USD","LU0788109394.HKD","SG9999014559.SGD","LU2602419157.SGD","LU0795875086.SGD","LU0098860793.USD","BK4516","BK4529","SG9999002232.USD","SMCC","LU0211327993.USD","LU1037948541.HKD","LU0170899867.USD","LU2294711713.HKD","LU2133065610.SGD","LU2430703178.SGD","LU2592432038.USD","LU2237957811.SGD","LU1121112475.USD","CALM","ARWR","PUI","LU1674673691.USD","UXI","HK0000914686.HKD","OXY","LU1778281490.HKD","LU1261432733.SGD","LU0823414478.USD","LU1116320737.USD","LU0122376428.USD","LU1621768115.EUR","LU2384288077.EUR","GEV","LU1116320901.HKD","LU0210528500.USD","SGXZ23171101.USD","LU1267930813.SGD","LU0053671581.USD","LU1093756168.USD","LU0154236417.USD","LU0310799852.SGD","RCTR","LU0612318385.USD","LU1430597077.USD","LU0683600562.USD","IGE","LU1861215975.USD","SG9999011175.SGD","BK4507","LU1894683348.USD","LU2487616109.SGD","BK4581","LU1169590202.USD","SG9999001440.SGD","LU0256863811.USD","LU2381873111.SGD","LU2264538146.SGD","LU2404859741.USD","XOMX","LU0070217475.USD","LU1303367103.USD","UGE","LU2357627491.SGD","LU0265550359.USD","POWR","BK4121","CAH","LU0466842654.USD","IE00BGHQF524.EUR","LU1839511570.USD","LU0640476718.USD","IE00B1XK9C88.USD","LU2249611893.SGD","LU0149725797.USD","LU1066051811.HKD","LU2065170008.USD","LU1621768206.USD","LU0124676726.USD","LU0345780950.USD","BK4084","LU0048573561.USD","LU1043141396.HKD","LU0320765646.SGD","COR","BK4175","LU1228905037.USD","LU0234572021.USD","LU0690374961.EUR","LU1582986359.USD","SG9999014575.USD","FRNW","LU2125154778.USD","LU0882574055.USD","LU1032466523.USD","LU2098885051.SGD","LU1366192091.USD","XLE","LU0823414551.USD","IE00BWXC8680.SGD","LU0630314457.HKD","LU0965509010.AUD","LU0251131958.USD","LU0456854461.SGD","LU2468319806.SGD","LU1069347547.HKD","LU0426417589.USD","XOM","LU1978683503.SGD","TEXU","LU0203345920.USD","IE00BKDWB100.SGD","LU0114720955.EUR","LU2129689605.HKD","LU1732800096.USD","LU0787776722.HKD","IE00BFXG1179.USD","LU1914381329.SGD","LU1934455863.HKD","BK4588","LU0889566641.SGD","LU0162691827.USD","IE0002270589.USD","LU1066051498.USD","SMCZ","LU2168564495.EUR","LU0368265418.SGD","LU0208291251.USD","LU1585245621.USD","LU0122379950.USD","LU1061106388.HKD","LU2498475776.HKD","TRUO","NICO","LU1674673428.USD","LU0654597011.USD","LU0072461881.USD","LU0612318971.USD","SMYY","TRUI","LU2357125470.USD","BK4115","LU2112291526.USD","LU2065171311.SGD","LU0251142724.SGD","LU2168564222.USD","IE0004086264.USD","LU0300736062.USD","BK4139","IE00B19Z3581.USD","LU0265550946.USD","LU1983260115.SGD","OSUR","SG9999014542.SGD","LU1988902786.USD","LU2505996681.GBP","SMRF","CVX","BK4559","IYE","LU0128525689.USD","IE00B3CCJ963.GBP","LU1064131342.USD","LU2089984988.USD","LU2168564065.EUR","LU2129689431.USD","GEVG","IE00B2Q91V27.USD","SMCY","BK4592","IYZ","BK4515","LU1582987597.SGD","BK4543","LU0345770308.USD","BK4533","LU0859254822.USD","EXI","BK4505","CLDX","FENY","LU0912757837.SGD","LU1496350502.SGD","LU1983299246.USD","LU0417517546.SGD","FTXN","BK4598","LU1228905540.USD","BK4075","LU0345770993.USD","LU1150488218.USD","LU0070302665.USD","LU1169589451.USD","LU1621767737.EUR","LU2347655156.SGD","IXC","LU1582987324.SGD","T","DYN","IE00BSNM7G36.USD","LU0310800965.SGD","IE0004091025.USD","SMCX","XLP","FSTA","SG9999002521.SGD","LU0965508806.USD","LU0545562505.USD","LU1880398554.USD","LU1582986433.USD","LU0689626769.HKD","LU0868494708.USD","LU2125154935.USD","BK4534","LU1066051225.USD","IE000M9KFDE8.USD","LU2462611646.USD","BK4213","GXPE","LU0053666078.USD","LU1883866441.USD","LU0320765489.SGD","OILT","LU0211326839.USD","IE00B19Z3B42.SGD","IE00B1BXHZ80.USD","LU1162221912.USD","LU0124384867.USD","LU1057294990.SGD","LU1894683264.USD","LU2298322129.HKD","BLFS","LU0738911758.USD","LU1934455194.USD","SMCI","LU0058720904.USD","TRUN","LU0266512473.USD","BK4550","LU1119994496.HKD","LU1929549753.HKD","LU0985489474.SGD","LU1732799900.SGD","LU0433182093.SGD","LU1621767810.EUR","ERX","BK4585","LU1718418525.SGD","LU1043141123.HKD","DVN","WEEI","SG9999015358.SGD","BK4566","LU1074936037.SGD","GEVX","LU2065171402.SGD","LU2324357040.USD","LU2543165471.USD","LU0052756011.USD","LU0942090050.USD","LU0868494617.USD","GB00B4LPDJ14.GBP","LU1037948897.HKD","BK4212","IE00B7SZLL34.SGD","SG9999014567.USD","LU0266512127.USD","SG9999015341.SGD","LU0203347892.USD","CGDG","CNRG","LU1861220033.SGD","XOMO","LU0068578508.USD","LU1430594728.SGD","BK4170","LU2360032135.SGD","SG9999004303.SGD","LU0949170772.SGD","LU2102340556.USD","BK4570","LU0742534661.SGD","LU2087621335.USD","LU0314106906.USD","DIG","LU0256331488.USD","SMCL","LU2430703095.HKD","LU0724618433.USD","BK4201","LU0278409577.USD","PXE","LU2430703251.USD","LU1814569148.SGD","LU1489326972.SGD","LU0289739699.SGD","LU1506573853.SGD","LU1084165304.USD","LU1267930490.SGD","LU2168563687.JPY","LU1880398471.USD","JOUL","HK0000914660.USD","LU0878866978.SGD","LU0965509283.SGD","LU2129689514.USD","LU0432979614.USD","NUKX","LU0994945656.USD","XOMZ","LU0300736492.USD","PM","LU1035773651.USD","LU0211326755.USD","LU0426412945.USD","LU0661504455.SGD","LU2506951792.HKD","LU1066053197.SGD","DRLL","LU1496350171.SGD","LU0965509101.SGD","BK4182","LU2237438978.USD","IE0034235303.USD","LU1150488135.SGD","LU1267930227.SGD","LU1934455277.USD","LU0496365809.HKD","MCK","SG9999003800.SGD","GB00B4QBRK32.GBP","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653376342","title":"Celldex Therapeutics Shares Down 2.6% After Scrapping Development of Skin Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2653376342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653376342?lang=en_us&edition=fundamental","pubTime":"2026-07-22 21:34","pubTimestamp":1784727271,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nFWN43O0DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653768121","title":"Analysts Are Bullish on Top Healthcare Stocks: Vanda (VNDA), Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653768121","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653768121?lang=en_us&edition=fundamental","pubTime":"2026-07-22 20:50","pubTimestamp":1784724608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vanda (VNDA) and Celldex (CLDX) with bullish sentime...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-vanda-vnda-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-vanda-vnda-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VNDA","CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653075200","title":"Celldex price target lowered to $61 from $67 at Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2653075200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653075200?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:35","pubTimestamp":1784720120,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald lowered the firm’s price target on Celldex (CLDX) to $61 from $67 and keeps an Overweight rating on the shares. Celldex’s Phase 2...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-price-target-lowered-to-61-from-67-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-price-target-lowered-to-61-from-67-at-cantor-fitzgerald-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653752199","title":"Celldex Therapeutics is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2653752199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653752199?lang=en_us&edition=fundamental","pubTime":"2026-07-22 19:27","pubTimestamp":1784719620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings(END) Dow Jones NewswiresJuly 22, 2026 07:27 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653575416","title":"Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653575416","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653575416?lang=en_us&edition=fundamental","pubTime":"2026-07-22 18:57","pubTimestamp":1784717842,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Buy rating on Celldex yesterday and set a price target of $48.00. The company’s shares closed yester...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","PGF"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":-0.0136},{"period":"1month","weight":0.1684},{"period":"3month","weight":0.3024},{"period":"6month","weight":0.3453},{"period":"1year","weight":0.8796},{"period":"ytd","weight":0.5177}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.475,"avgChangeRate":0.004594},{"month":4,"riseRate":0.5,"avgChangeRate":0.003159},{"month":5,"riseRate":0.275,"avgChangeRate":-0.021672},{"month":6,"riseRate":0.512195,"avgChangeRate":0.146914},{"month":7,"riseRate":0.439024,"avgChangeRate":-0.012125},{"month":8,"riseRate":0.390244,"avgChangeRate":-0.025229},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}